Solving clinical research challenges: an IT perspective
At Medidata NEXT in New York, we sat down with Jackie Kent, Medidata’s senior vice...
Funding for costly next-gen therapies: is reinsurance the answer?
Unlike traditional small molecules or biologics, cell and gene therapies for debilitating diseases are administered...
BMS acquires Celgene for an equity value of $74bn
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a...
Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics
Sanofi has returned worldwide rights to all programmes that were covered under a licence and...
Pharma companies break 2018 price freeze
On 1 January approximately 30 pharmaceutical companies raised the prices of hundreds of drugs in...
CEPI bids to self-amplify mRNA vaccine platform to tackle infectious diseases
GlobalData believes that mRNA vaccines may be more favourable to DNA vaccines because they do...
NASH market forecast to be worth $18.3bn by 2026
Due to increasing rates of obesity and diabetes, non-alcoholic steatohepatitis (NASH), a chronic inflammatory liver...
The industry shift to anti-tau therapies to treat Alzheimer’s
Eisai announced an extended collaboration with University College London (UCL) in the development of the...
GSK and Pfizer opt for leaner structure by merging consumer units
GlaxoSmithKline (GSK) and Pfizer have agreed to merge their respective consumer business units, in a...
Irish authorities demand €1.6bn in back tax from Perrigo
The Irish tax authority Revenue Commissioners has issued a Notice of Amended Assessment (NoA) to...